Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in recent months. According to ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Revenue rose 10% to $3.79 billion, surpassing the average $3.74 billion target from analysts polled by FactSet. Sales of the EYLEA HD more than doubled to $305 million. The medication was approved for ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...